Miguel Quintela-Fandino (M Quintela-Fandino)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Venues

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Breast cancer research : BCR

Clinical cancer research : an official journal of the American Association for Cancer Research

Nature communications

Universidad Autonoma de Madrid

Universidad Autonoma de Barcelona (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universidad Autonoma de Madrid

Spain

Associate Professor :: Precision Oncology Chair, Department of Medicine

Spanish National Cancer Research Centre

Spain

Director :: Clinical Program

Hospital Quirón Madrid

Spain

Head of Drug Development Unit :: Medical Oncology Department

Spanish National Cancer Research Centre Apr 01 2010

Spain

Head of Breast Cancer Clinical Research Unit :: Clinical Research Program

MD Anderson Cancer Center Madrid

Spain

Staff physician :: Medical Oncology Department

Hospital Universitario 12 de Octubre Jul 15 2005 - Dec 01 2005

Spain

Médico adjunto

Hospital Universitario 12 de Octubre Jul 15 2001 - Jul 15 2005

Spain

Medico Interno Residente

Education History

Universidad Autonoma de Barcelona - Oct 01 2005

Spain

MSC

Universidad Complutense de Madrid - Sep 27 2005

Spain

PHD

Publications

Miguel Quintela-Fandino, Begoña Bermejo, Esther Zamora Adelantado, Fernando Moreno Antón, José Angel García-Saenz, Sonia Pernas, Noelia Martínez Jáñez, Desirée Jiménez, Encarna Adrover, R Andrés Conejero, Silvana Mourón, Maria Jose Bueno, Luis Manso Sanchez, Gemma Viñas, Emilio Alba, Antonio Llombart, Javier Cortes, Cristina Tebar, Denise J Roe, Adam Grant, Adam W Watson, Ramón Colomer, Ghassan Mouneimne
High mechanical conditioning by tumor extracellular matrix stiffness is a predictive biomarker for anti-fibrotic therapy in HER2-negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Maria Jose Bueno, Silvana Mouron, Eduardo Caleiras, Mario Martínez, Luis Manso, Ramón Colomer, Miguel Quintela-Fandino
Distribution of PD-L1, TROP2 and HER2- "lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Rebeca Jimeno, Silvana Mouron, Roberto Salgado, Sherene Loi, Belén Pérez-Mies, Rodrigo Sánchez-Bayona, Luis Manso, Mario Martínez, Ana Garrido-García, Rosario Serrano-Pardo, Ramón Colomer, Miguel Quintela-Fandino
Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 25 (4) (2022)
Rebeca Jimeno, Silvana Mouron, Roberto Salgado, Sherene Loi, Belén Pérez-Mies, Rodrigo Sánchez-Bayona, Luis Manso, Mario Martínez, Ana Garrido-García, Rosario Serrano-Pardo, Ramón Colomer, Miguel Quintela-Fandino
Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 25 (4) (2022)
Rebeca Jimeno, Silvana Mouron, Roberto Salgado, Sherene Loi, Belén Pérez-Mies, Rodrigo Sánchez-Bayona, Luis Manso, Mario Martínez, Ana Garrido-García, Rosario Serrano-Pardo, Ramón Colomer, Miguel Quintela-Fandino
Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 25 (4) (2022)
S Mouron, Maria Jose Bueno, Ana Lluch, Luis Manso Sanchez, I Calvo, Javier Cortes, José Angel García-Saenz, M Gil-Gil, N Martinez-Janez, J V Apala, E Caleiras, Pilar Ximénez-Embún, J Muñoz, L Gonzalez-Cortijo, R Murillo, R Sánchez-Bayona, J M Cejalvo, G Gómez-López, Coral Fustero-Torre, Sergio Sabroso-Lasa, Núria Malats, M Martinez, A Moreno, D Megias, Marcos Malumbres, Ramón Colomer, Miguel Quintela-Fandino
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. Nature communications 13 (1) (2022)
Rebeca Jimeno, Silvana Mouron, Roberto Salgado, Sherene Loi, Belén Pérez-Mies, Rodrigo Sánchez-Bayona, Luis Manso, Mario Martínez, Ana Garrido-García, Rosario Serrano-Pardo, Ramón Colomer, Miguel Quintela-Fandino
Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 25 (4) (2022)
Rebeca Jimeno, Silvana Mouron, Roberto Salgado, Sherene Loi, Belén Pérez-Mies, Rodrigo Sánchez-Bayona, Luis Manso, Mario Martínez, Ana Garrido-García, Rosario Serrano-Pardo, Ramón Colomer, Miguel Quintela-Fandino
Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
Atish D Choudhury, Celestia S Higano, Johann S de Bono, Natalie Cook, Dana E Rathkopf, Kari B Wisinski, Juan Martin-Liberal, Mark Linch, Elisabeth I Heath, Richard D Baird, Javier García Corbacho, Miguel Quintela-Fandino, Simon T Barry, Elza C de Bruin, Steve Colebrook, George Hawkins, Teresa Klinowska, Brijesh Maroj, Ganesh Moorthy, Peter G S Mortimer, Michele Moschetta, Myria Nikolaou, Liz Sainsbury, Geoffrey I Shapiro, Lillian L Siu, Aaron Richard Hansen
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (11) (2022)
Silvana Mouron, Luis Manso, Eduardo Caleiras, Jose L Rodriguez-Peralto, Oscar M Rueda, Carlos Caldas, Ramon Colomer, Miguel Quintela-Fandino, Maria J Bueno
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. Breast cancer research : BCR 23 (1) (2021)
Miguel Quintela-Fandino, Esther Holgado, Luis Manso, Serafin Morales, Begoña Bermejo, Ramon Colomer, Juan V Apala, Raquel Blanco, Manuel Muñoz, Eduardo Caleiras, Vega Iranzo, Mario Martinez, Orlando Dominguez, Javier Hornedo, Lucia Gonzalez-Cortijo, Javier Cortes, Ariadna Gasol Cudos, Diego Malon, Antonio Lopez-Alonso, María C Moreno-Ortíz, Silvana Mouron, Santos Mañes
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast cancer research : BCR 22 (1) (2020)

Miguel Quintela-Fandino.css-eqlu8i{font-size:small;padding-left:4px;} (M Quintela-Fandino)

Publication Activity (10 Years)

Top Topics

Top Venues

Miguel Quintela-Fandino (M Quintela-Fandino)